IP Group-backed Pulmocide Discontinues Late-stage Trial of Pulmonary Aspergillosis Treatment

10:57 AM EST, 01/07/2026 (MT Newswires) -- IP Group's (IPO.L) 12%-owned Pulmocide Ltd. will terminate the Opera-T phase 3 study of opelconazole for treating refractory invasive pulmonary aspergillosis, a complication of lung transplantation. The London-listed investor said Wednesday that Pulmocide will carry out a thorough review of the trial's unblinded data to assess potential next steps for the program.